Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10808044 | 0.87 | HTT (0.77) | HTTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL11067980 | 0.84 | HTT (0.73) | HTTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL7109768 | 0.82 | HTT (0.69) | HTTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL334530 | 0.81 | ALDH1A1 (1.00) | HTTALDH1A1SMN1; SMN2FKBP1AHPGD | |
| SCHEMBL11678919 | 0.80 | HPGD (0.70) | HTTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL30872952 | 0.79 | ALDH1A1 (0.71) | HTTALDH1A1SMN1; SMN2FKBP1AHPGD | |
| SCHEMBL1879618 | 0.79 | ALDH1A1 (0.71) | HTTALDH1A1SMN1; SMN2FKBP1AHPGD | |
| SCHEMBL27183042 | 0.79 | ALDH1A1 (0.71) | HTTALDH1A1SMN1; SMN2FKBP1AHPGD | |
| SCHEMBL1111199 | 0.78 | HTT (0.64) | HTTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL11067449 | 0.78 | HTT (0.63) | HTTALDH1A1SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | HTT 868/4885ALDH1A1 1939/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.